(S)-乙酰基氨基环己基乙酸 | 78781-84-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-乙酰基氨基环己基乙酸
• 英文名称: (+)-(2S)-N-Acetyl-2-cyclohexylglycin
• 英文别名: (S)-acetylamino-cyclohexyl-acetic acid；(S)-2-acetamido-2-cyclohexylacetic acid；acetyl-cyclohexylglycine；(S)-Acetylaminocyclohexylacetic acid；(2S)-2-acetamido-2-cyclohexylacetic acid
• CAS: 78781-84-7
• 化学式: C₁₀H₁₇NO₃
• 分子量: 199.25
• InChiKey: CVVVAKVOCWNDLJ-VIFPVBQESA-N

物化性质

• 沸点：
  428.6±28.0 °C(Predicted)
• 密度：
  1.134±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-acetamido-2-phenylethyl (2S)-2-acetamido-2-((R)-cyclohex-2-en-1-yl)acetate 在 palladium on activated charcoal 硫酸 、 氢气 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 4.0h， 生成 (S)-乙酰基氨基环己基乙酸
  参考文献：
  名称：

  Santoso, Sentot; Kemmer, Thorsten; Trowitzsch, Wolfram, Liebigs Annalen der Chemie, 1981, # 4, p. 642 - 657

  摘要：

  DOI：

文献信息

• [EN] CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DES CYSTÉINE PROTÉASES
  申请人：MEDIVIR UK LTD

  公开号：WO2011070541A1

  公开（公告）日：2011-06-16

  Compounds of the formula (I) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or -CH2C3-C7 cycloalkyl; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylamino or C1-C6dialkylamino; for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

  化合物的公式（I）中，其中R1a为H；而R1b为C1-C6烷基，碳环烷基或杂环基；或者R1a和R1b一起定义为具有3-6个环原子的饱和环胺；R2a和R2b独立地为H，卤素，C1-C4烷基，C1-C4卤代烷基或C1-C4烷氧基，或R2a和R2b与它们连接的碳原子一起形成C3-C6环烷基；R3是支链C5-C10烷基链，C2-C4卤代烷基或-CH2C3-C7环烷基；R4为C1-C6烷基，C1-C6卤代烷基，C1-C6烷基氨基或C1-C6二烷基氨基；用于预防或治疗由于cathepsin S的不当表达或激活而表现出的紊乱的疾病。
• Facile Asymmetric Synthesis of α-Amino Acids Employing Chiral Ligand-Mediated Asymmetric Addition Reactions of Phenyllithium with Imines
  作者：Masayoshi Hasegawa、Daisuke Taniyama、Kiyoshi Tomioka

  DOI：10.1016/s0040-4020(00)00860-7

  日期：2000.12

  A three-step methodology involving an external chiral ligand-mediated asymmetric addition of phenyllithium to an anisidine imine, oxidative removal of N-PMP group, and finally oxidative conversion of the phenyl group to a carboxyl group provides a facile synthesis of optically pure α-amino acid derivatives bearing a bulky α-substituent.

  这是一个三步法，涉及外部手性配体介导的苯胺向茴香胺亚胺的不对称加成，N -PMP基团的氧化去除，最后苯基基团向羧基的氧化转化，可以轻松合成光学纯的α-具有庞大的α-取代基的氨基酸衍生物。
• Heterocyclic aromatic oxazole compounds and use thereof
  申请人：——

  公开号：US20020198244A1

  公开（公告）日：2002-12-26

  A heterocyclic aromatic oxazole compound of the formula (I) 1 wherein Z is an oxygen atom; one of R and R 1 is a group of the formula 2 wherein R 3 is lower alkyl, amino or lower alkylamino, and R 4 , R 5 , R 6 and R 7 are the same or different and each is hydrogen atom, halogen atom, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy or amino, provided that at least one of R 4 , R 5 , R 6 and R 7 is not hydrogen atom, and the other is an optionally substituted cycloalkyl, an optionally substituted heterocyclic group or an optionally substituted aryl; and R 2 is a lower alkyl or a halogenated lower alkyl, and a pharmaceutically acceptable salt thereof. The heterocyclic aromatic oxazole compound and pharmaceutically acceptable salts thereof have antipyretic action, analgesic action, anti-inflammatory action, and particularly, selective inhibitory action on cyclooxygenase-2 (COX-2), and are expected to be useful as anti-inflammatory agents with less side-effects such as digestive tract disorders.

  式(I)中，Z为氧原子；R和R1中的一个为式2的基团，其中R3为低碳基、氨基或低碳基氨基，R4、R5、R6和R7相同或不同，且每个为氢原子、卤素原子、低碳基、低碳氧基、三氟甲基、羟基或氨基，但至少有一个为非氢原子，另一个为可选取代的环烷基、可选取代的杂环基或可选取代的芳基；R2为低碳基或卤代低碳基，以及其药学上可接受的盐。该杂环芳香族噁唑化合物及其药学上可接受的盐具有退热作用、镇痛作用、抗炎作用，特别是对环氧合酶-2 (COX-2)的选择性抑制作用，并有望作为抗炎剂使用，具有较少的消化道副作用。
• CYSTEINE PROTEASE INHIBITORS
  申请人：Ayesa Susana

  公开号：US20120283305A1

  公开（公告）日：2012-11-08

  Compounds of the formula I wherein R 1a is H; and R 1b is C 1 -C 6 alkyl, Carbocyclyl or Het; or R 1a and R 1b together define a saturated cyclic amine with 3-6 ring atoms; R 2a and R 2b are independently H, halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl or C 1 -C 4 alkoxy, or R 2a and R 2b together with the carbon atom to which they are attached form a C 3 -C 6 cycloalkyl; R 3 is a branched C 5 -C 10 alkyl chain, C 2 -C 4 haloalkyl or —CH 2 C 3 -C 7 cycloalkyl; R 4 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkylamino or C 1 -C 6 dialkylamino; for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

  化合物的公式I，其中 R1a是H；而R1b是C1-C6烷基，碳环基或杂环基；或者R1a和R1b共同定义一个由3-6个环原子组成的饱和环胺； R2a和R2b独立地是H，卤素，C1-C4烷基，C1-C4卤代烷基或C1-C4烷氧基，或者R2a和R2b与它们附着的碳原子一起形成一个C3-C6环烷基； R3是支链C5-C10烷基链，C2-C4卤代烷基或-CH2C3-C7环烷基； R4是C1-C6烷基，C1-C6卤代烷基，C1-C6烷基氨基或C1-C6二烷基氨基； 用于预防或治疗以cathepsin S不适当表达或激活为特征的疾病。
• HETEROAROMATIC OXAZOLE COMPOUNDS AND USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：EP0745596A1

  公开（公告）日：1996-12-04

  A heterocyclic aromatic oxazole compound of the formula (I) wherein Z is an oxygen atom; one of R and R1 is a group of the formula wherein R3 is lower alkyl, amino or lower alkylamino, and R4, R5, R6 and R7 are the same or different and each is hydrogen atom, halogen atom, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy or amino, provided that at least one of R4, R5, R6 and R7 is not hydrogen atom, and the other is an optionally substituted cycloalkyl, an optionally substituted heterocyclic group or an optionally substituted aryl; and R2 is a lower alkyl or a halogenated lower alkyl, and a pharmaceutically acceptable salt thereof. The heterocyclic aromatic oxazole compound and pharmaceutically acceptable salts thereof have antipyretic action, analgesic action, anti-inflammatory action, and particularly, selective inhibitory action on cyclooxygenase-2 (COX-2), and are expected to be useful as anti-inflammatory agents with less side-effects such as digestive tract disorders.

  式（I）的杂环芳香族噁唑化合物 其中 Z 是氧原子；R 和 R1 中的一个是式中的基团 其中 R3 是低级烷基、氨基或低级烷基氨基，R4、R5、R6 和 R7 相同或不同，且各自是氢原子、卤素原子、低级烷基、低级烷氧基、三氟甲基、羟基或氨基，条件是 R4、R5、R6 和 R7 中至少有一个不是氢原子，另一个是任选取代的环烷基、任选取代的杂环基团或任选取代的芳基；以及 R2 是低级烷基或卤代低级烷基，及其药学上可接受的盐。杂环芳香族噁唑化合物及其药学上可接受的盐具有解热作用、镇痛作用、抗炎作用，特别是对环氧化酶-2（COX-2）具有选择性抑制作用，可望作为副作用较少（如消化道功能紊乱）的抗炎药物。